Sorted By:


World Cancer Day: Reflecting on progress and hope for the future in cancer treatment

PhRMA  |  Blog Post

And researchers are continuing to better understand the inner workings and underlying mechanisms of cancers every day.

MIT scientists find evidence that Alzheimer’s ‘lost memories’ may one day be recoverable

From Hope To Cures  |  From Our Network

The achievements of a distinguished 30-year career.

Over 8,200 Clinical Trials of Medicines Conducted by Texas Research Institutions Since 1999

PhRMA  |  Press Release

Among the 914 clinical trials still recruiting patients in the state, there are trials of a genetically-modified vaccine to treat melanoma, a fusion protein to treat diabetic macular edema and a new antibody that targets lupus and various cancers.

PhRMA Launches “I’m Not Average” Campaign to Highlight the Stories of Cancer Survivors

PhRMA  |  Press Release

Since the mid-1970s, the 5-year survival rate has climbed to 68 percent and survival rates for childhood cancers are up 58 percent.

Week in Review: The latest from PhRMA

PhRMA  |  Blog Post

Read more about these innovations and the ongoing fight against leukemia and lymphoma.

Australia’s opportunity to lead the TPP forward

PhRMA  |  Blog Post

Wayne Taylor, of the Canada-based Cameron Institute, recently wrote: “Innovative medicines today are conquering cancers and rare diseases that were thought to be unconquerable 10 years ago.

Biogen CEO George A. Scangos Becomes PhRMA Board Chairman

PhRMA  |  Press Release

During his 27 year career at Johnson & Johnson, Joaquin has had experiences in sales, marketing and general management.

Mae Jemison

PhRMA  |  Biography

Throughout Jemison’s career, she has worked internationally including in a Cambodian refugee camp with the Flying Doctors of East Africa.

The Best Kind of Progress: Cancer Medicines and the Value They Bring to Us All

PhRMA  |  Blog Post

The biopharmaceutical industry works hard every day to achieve this progress and the results are strong: The U.S. cancer death rate is down 20 percent since the all-time high in 1991 Since the mid-1970s, survival rates are up 58 percent for childhood cancers, 54 percent for lung cancer, 50 percent for prostate cancer, 36 percent for colon cancer and 21 percent for breast cancer.

Why Do More Black Women Die of Breast Cancer? A Study Aims To Find Out

From Hope To Cures  |  From Our Network

There might be some genetic risk factors that are actually contributing to the fact that black women tend to get more aggressive breast cancers.

Dr. William Chin to Lead Science & Regulatory Affairs

PhRMA  |  Press Release

Chin is an internist and endocrinologist who spent much of his early career studying the molecular mechanisms of hormonal control of gene expression.

Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman

PhRMA  |  Press Release

Representing the biopharmaceutical industry has been one of the most rewarding experiences of my career and I am very proud of the incredible work our members do every day to improve the lives of patients,” said Castellani.

Who gets a seat at ICER’s table? Hint: It’s not patients

PhRMA  |  Blog Post

In comments submitted to ICER, the Association of Community Cancers encouraged ICER to “limit voting members of panels to subject matter experts in the health interventions and disease areas being reviewed …” In PhRMA’s recent comments to ICER, we recommended that they meaningfully engage with stakeholders from the start to the finish of the value assessment process, including in priority setting and development of their evidence reports.

Inside The Race To Diagnose Cancer From A Simple Blood Draw

From Hope To Cures  |  From Our Network

At the time, there was one FDA-approved liquid biopsy on the market, Janssen Diagnostics’s CellSearch, a device that counts the number of circulating tumor cells (CTCs) in the blood of patients with metastatic breast, colon, and prostate cancers to predict a good or bad prognosis.

PhRMA Supports Stand Up To Cancer’s Mission of Promoting Cancer Research

PhRMA  |  Press Release

That’s why the Pharmaceutical Research and Manufacturers of America (PhRMA) supports Stand Up To Cancer’s (SU2C) mission of promoting and accelerating groundbreaking clinical research into the discovery and development of new medicines to treat cancers.

Week in Review: Collaboration for Patient Progress

PhRMA  |  Blog Post

On Monday, we proudly supported the Ruesch Center for the Cure of Gastrointestinal Cancers’ discussion on the present state and future promise for GI cancer patients.

A Life-Saving Life’s Work: A Story on the Impact of Clinical Trials

PhRMA  |  Blog Post

During my career at Quintiles, I’ve had the honor of seeing firsthand the impact of the meaningful work we do for patients – including developing breakthrough treatments for cystic fibrosis, breast cancer and diabetes.

Director - International Advocacy

PhRMA  |  PhRMA Career

We are committed to supporting our family of professionals at PhRMA and strive to create programs that help our team members manage the challenges of balancing a fast-paced career with their own personal goals.

Targeting the immune system, not the tumor

PhRMA  |  Blog Post

Researchers hope to replace chemotherapy as the first line treatment for many cancers and help as many patients as possible achieve long-term survival.

Connecting Some Dots on Innovation

PhRMA  |  Blog Post

The health benefits for patients resulting from all this R&D are impressive: for example, in recent years we've seen declining death rates for cardiovascular disease, HIV/AIDS and even for cancers.

Taking the Necessary Steps to Make the Cancer Moonshot Work

From Hope To Cures  |  From Our Network

Unfortunately, some cancers aren’t as well known or sufficiently resourced as others.

New Chart Pack: Big Strides in Fight Against Cancer

PhRMA  |  Blog Post

There are more than 1,000 medicines in development for various cancers – and 73% of those have the potential to be personalized medicines.

Making Chemo More Tolerable

From Hope To Cures  |  From Our Network

But the drugs don’t work in all cancers.

The Future of Clinical Pathways

PhRMA  |  Blog Post

Some estimate that approximately 80 percent of patients benefit from adherence to a pathway and 20 percent need some variation, but even that can vary across cancers.

Burden on Patients: 5 Questions on Access to Diabetes Medicines in Health Exchange Plans

PhRMA  |  Blog Post

Question (Allyson Funk): Can you tell me about you, your career representing patients and what you’ve learned over the years representing patients with diabetes?

You have reviewed the first 250 results out of 264. Each page contains 25 results. You're on page 10.

prev 7 8 9 10 11 next